National Practice Patterns in the Management of the Regional Lymph Node Basin After Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
22
06
2022
accepted:
19
07
2022
pubmed:
26
8
2022
medline:
11
11
2022
entrez:
25
8
2022
Statut:
ppublish
Résumé
Immediate completion lymph node dissection (CLND) for patients with sentinel lymph node (SLN) metastasis from cutaneous melanoma has been replaced largely by ultrasound nodal surveillance since the publication of two landmark trials in 2016 and 2017. National practice patterns of CLND remain poorly characterized. Patients with a diagnosis of cutaneous melanoma in 2016 and 2018 without clinical nodal disease who underwent sentinel lymph node biopsy (SLNB) were identified from the National Cancer Database (NCDB). Characteristics associated with CLND were analyzed by uni- and multivariate logistic regression. Overall survival (OS) was estimated using Kaplan-Meier and Cox proportional hazards regression analyses. Of the 3517 patients included in the study, 1405 had disease diagnosed in 2016. The patients with cutaneous melanoma diagnosed in 2016 had a median age of 60 years and a tumor thickness of 2.3 mm compared to 62 years and 2.4 mm, respectively, for the patients with cutaneous melanoma diagnosed in 2018. According to the NCDB, 40 % (n = 559) of the patients underwent CLND in 2016 compared with 6 % (n = 132) in 2018. The factors associated with receipt of CLND in 2018 included younger age (odds ratio [OR], 0.97; 95 % confidence interval [CI], 0.95-0.99; p = 0.001), rural residence (OR, 3.96; 95 % CI, 1.50-10.49; p = 0.006), head/neck tumor location (OR, 1.88; 95 % CI, 1.10-3.23; p = 0.021), and more than one positive SLN (OR, 1.80; 95 % CI, 1.17-2.76; p = 0.007). The 5-year OS did not differ between the patients who received SLNB only and those who underwent CLND (hazard ratio [HR], 0.93; p = 0.54). The rates of CLND have decreased nationally. However, patients with head/neck primary tumors who live in rural locations are more likely to undergo CLND, highlighting populations for which treatment may be non-uniform with national practice patterns.
Sections du résumé
BACKGROUND
BACKGROUND
Immediate completion lymph node dissection (CLND) for patients with sentinel lymph node (SLN) metastasis from cutaneous melanoma has been replaced largely by ultrasound nodal surveillance since the publication of two landmark trials in 2016 and 2017. National practice patterns of CLND remain poorly characterized.
METHODS
METHODS
Patients with a diagnosis of cutaneous melanoma in 2016 and 2018 without clinical nodal disease who underwent sentinel lymph node biopsy (SLNB) were identified from the National Cancer Database (NCDB). Characteristics associated with CLND were analyzed by uni- and multivariate logistic regression. Overall survival (OS) was estimated using Kaplan-Meier and Cox proportional hazards regression analyses.
RESULTS
RESULTS
Of the 3517 patients included in the study, 1405 had disease diagnosed in 2016. The patients with cutaneous melanoma diagnosed in 2016 had a median age of 60 years and a tumor thickness of 2.3 mm compared to 62 years and 2.4 mm, respectively, for the patients with cutaneous melanoma diagnosed in 2018. According to the NCDB, 40 % (n = 559) of the patients underwent CLND in 2016 compared with 6 % (n = 132) in 2018. The factors associated with receipt of CLND in 2018 included younger age (odds ratio [OR], 0.97; 95 % confidence interval [CI], 0.95-0.99; p = 0.001), rural residence (OR, 3.96; 95 % CI, 1.50-10.49; p = 0.006), head/neck tumor location (OR, 1.88; 95 % CI, 1.10-3.23; p = 0.021), and more than one positive SLN (OR, 1.80; 95 % CI, 1.17-2.76; p = 0.007). The 5-year OS did not differ between the patients who received SLNB only and those who underwent CLND (hazard ratio [HR], 0.93; p = 0.54).
CONCLUSION
CONCLUSIONS
The rates of CLND have decreased nationally. However, patients with head/neck primary tumors who live in rural locations are more likely to undergo CLND, highlighting populations for which treatment may be non-uniform with national practice patterns.
Identifiants
pubmed: 36006494
doi: 10.1245/s10434-022-12364-9
pii: 10.1245/s10434-022-12364-9
doi:
Substances chimiques
Transforming Growth Factor beta
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8456-8464Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. Society of Surgical Oncology.
Références
Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609. https://doi.org/10.1056/NEJMoa1310460 .
doi: 10.1056/NEJMoa1310460
pubmed: 24521106
pmcid: 4058881
Bello DM, Faries MB. The Landmark Series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes). Ann Surg Oncol. 2020;27:15–21. https://doi.org/10.1245/s10434-019-07830-w .
doi: 10.1245/s10434-019-07830-w
pubmed: 31535299
Leong SP. Selective sentinel lymphadenectomy for malignant melanoma. Surg Clin North Am. 2003. https://doi.org/10.1016/S0039-6109(02)00206-2 .
doi: 10.1016/S0039-6109(02)00206-2
pubmed: 12744619
McMasters KM, Swetter SM. Current management of melanoma: benefits of surgical staging and adjuvant therapy. J Surg Oncol. 2003;82:209–16. https://doi.org/10.1002/jso.10216 .
doi: 10.1002/jso.10216
pubmed: 12619066
Cascinelli N, Clemente C, Bifulco C, et al. Do patients with tumor-positive sentinel nodes constitute a homogeneous group? Ann Surg Oncol. 2001;8(9 Suppl):35S–37S.
pubmed: 11599895
van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor, load, and Dewar topography criteria. J Clin Oncol. 2011;29:2206–14. https://doi.org/10.1200/JCO.2010.31.6760 .
doi: 10.1200/JCO.2010.31.6760
pubmed: 21519012
Ariyan C, Brady MS, Gönen M, Busam K, Coit D. Positive nonsentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16:186–90. https://doi.org/10.1245/s10434-008-0187-5 .
doi: 10.1245/s10434-008-0187-5
pubmed: 18979135
Guggenheim MM, Hug U, Jung FJ, et al. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma. Ann Surg. 2008;247:687–93. https://doi.org/10.1097/SLA.0b013e318161312a .
doi: 10.1097/SLA.0b013e318161312a
pubmed: 18362633
Faut M, Heidema RM, Hoekstra HJ, et al. Morbidity after inguinal lymph node dissections: it is time for, a change. Ann Surg Oncol. 2017;24:330–9. https://doi.org/10.1245/s10434-016-5461-3 .
doi: 10.1245/s10434-016-5461-3
pubmed: 27519351
Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757–67. https://doi.org/10.1016/S1470-2045(16)00141-8 .
doi: 10.1016/S1470-2045(16)00141-8
pubmed: 27161539
Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or observation for, sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22. https://doi.org/10.1056/NEJMoa1613210 .
doi: 10.1056/NEJMoa1613210
pubmed: 28591523
pmcid: 5548388
Leiter U, Stadler R, Mauch C, et al. Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol. 2019;37:3000–8. https://doi.org/10.1200/JCO.18.02306 .
doi: 10.1200/JCO.18.02306
pubmed: 31557067
Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:367–402. https://doi.org/10.6004/jnccn.2019.0018 .
doi: 10.6004/jnccn.2019.0018
pubmed: 30959471
Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American society of clinical oncology and society of surgical oncology clinical practice guideline update. Ann Surg Oncol. 2018;25:356–77. https://doi.org/10.1245/s10434-017-6267-7 .
doi: 10.1245/s10434-017-6267-7
pubmed: 29236202
Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90. https://doi.org/10.1245/s10434-007-9747-3 .
doi: 10.1245/s10434-007-9747-3
pubmed: 18183467
pmcid: 2234447
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–6. https://doi.org/10.1016/0197-2456(96)00075-x .
doi: 10.1016/0197-2456(96)00075-x
pubmed: 8889347
Downs JS, Gyorki DE. An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection? Melanoma Manag. 2019;6:24. https://doi.org/10.2217/mmt-2019-0011 .
doi: 10.2217/mmt-2019-0011
Ul-Mulk J, Hölmich LR. Lymph node dissection in patients with malignant melanoma is associated with high risk of morbidity. Dan Med J. 2012;59:A4441.
pubmed: 22677239
Kretschmer L, Thoms KM, Peeters S, Haenssle H, Bertsch HP, Emmert S. Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res. 2008;18:16–21. https://doi.org/10.1097/CMR.0b013e3282f2017d .
doi: 10.1097/CMR.0b013e3282f2017d
pubmed: 18227703
Moody JA, Botham SJ, Dahill KE, Wallace DL, Hardwicke JT. Complications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma: a systematic review of the literature. Eur J Surg Oncol. 2017;43:1760–7. https://doi.org/10.1016/j.ejso.2017.07.003 .
doi: 10.1016/j.ejso.2017.07.003
pubmed: 28756017
Dedivitis RA, Guimarães AV, Pfuetzenreiter EG, Castro MA. Neck dissection complications. Braz J Otorhinolaryngol. 2011;77:65–9. https://doi.org/10.1590/s1808-86942011000100011 .
doi: 10.1590/s1808-86942011000100011
pubmed: 21340191
Shaha AR. Complications of neck dissection for, thyroid cancer. Ann Surg Oncol. 2008;15:397–9. https://doi.org/10.1245/s10434-007-9724-x .
doi: 10.1245/s10434-007-9724-x
pubmed: 18058179
Montgomery KB, Correya TA, Broman KK. Real-world adherence to nodal surveillance for sentinel lymph node-positive melanoma. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-11839-z .
doi: 10.1245/s10434-022-11839-z
pubmed: 35608800
Arnold AC, Fleet R, Lim D. A case for, mandatory ultrasound training for, rural general practitioners: a commentary. Rural Remote Health. 2021;21:6328. https://doi.org/10.22605/RRH6328 .
doi: 10.22605/RRH6328
pubmed: 34237995
Stewart KA, Navarro SM, Kambala S, et al. Trends in ultrasound use in low and middle income countries: a systematic review. Int J MCH AIDS. 2020;9:103–20. https://doi.org/10.21106/ijma.294 .
doi: 10.21106/ijma.294
pubmed: 32123634
pmcid: 7031872
Bredbeck BC, Mubarak E, Zubieta DG, et al. Management of the positive sentinel lymph node in the post-MSLT-II era. J Surg Oncol. 2020;122:1778–84. https://doi.org/10.1002/jso.26200 .
doi: 10.1002/jso.26200
pubmed: 32893366
pmcid: 7752829
Nijhuis AAG, Spillane AJ, Stretch JR, et al. Current management of patients with melanoma who are found to be sentinel node-positive. ANZ J Surg. 2020;90:491–6. https://doi.org/10.1111/ans.15491 .
doi: 10.1111/ans.15491
pubmed: 31667924
Klemen ND, Han G, Leong SP, et al. Completion lymphadenectomy for, a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit. J Surg Oncol. 2019;119:1053–9. https://doi.org/10.1002/jso.25444 .
doi: 10.1002/jso.25444
pubmed: 30883771
Delgado AF. Complete lymph node dissection in melanoma: a systematic review and meta-analysis. Anticancer Res. 2017;37:6825–9. https://doi.org/10.21873/anticanres.12143 .
doi: 10.21873/anticanres.12143
pubmed: 29187461